SIL as Maintenance Therapy in Multiple Myeloma

Sponsor
Navy General Hospital, Beijing
Study ID
NCT06744894
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
14 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The goal of this phase 2 trial is to test the safety and efficacy of selinexor combined with ixazomib and lenalidomide as maintenance therapy in patients with multiple myeloma.

Key Dates

Start date
Jan 1, 2025
Status verified
Dec 2024
Primary completion
Jan 1, 2028
Completion
Jan 1, 2030

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Maintenance Therapy
    Patients were treated by Selinexor combined with Ixazomib and Lenalidomide as Maintenance Therapy

Primary Outcome Measure

PFS [ Time Frame: 2 years ]

Central Contacts

Related Studies